Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-Current Assets (2016 - 2025)

Voyager Therapeutics' Non-Current Assets history spans 11 years, with the latest figure at $49.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 57.34% year-over-year to $49.6 million; the TTM value through Dec 2025 reached $320.6 million, up 12.9%, while the annual FY2025 figure was $49.6 million, 57.34% down from the prior year.
  • Non-Current Assets for Q4 2025 was $49.6 million at Voyager Therapeutics, down from $68.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $116.2 million in Q4 2024 and bottomed at $31.6 million in Q4 2023.
  • The 5-year median for Non-Current Assets is $54.1 million (2022), against an average of $56.7 million.
  • The largest annual shift saw Non-Current Assets surged 267.89% in 2024 before it tumbled 57.34% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $57.2 million in 2021, then crashed by 39.02% to $34.9 million in 2022, then fell by 9.35% to $31.6 million in 2023, then soared by 267.89% to $116.2 million in 2024, then crashed by 57.34% to $49.6 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Non-Current Assets are $49.6 million (Q4 2025), $68.7 million (Q3 2025), and $94.2 million (Q2 2025).